• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房颤动患者的多种合并症。

Multimorbidity in patients with atrial fibrillation.

机构信息

Department of Cardiology, UMCG, Groningen, The Netherlands.

Department of Cardiology, UMCG, Groningen, The Netherlands

出版信息

Open Heart. 2024 Mar 19;11(1):e002641. doi: 10.1136/openhrt-2024-002641.

DOI:10.1136/openhrt-2024-002641
PMID:38508658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10952871/
Abstract

There is an escalating trend in both the incidence and prevalence of atrial fibrillation (AF). AF is linked to numerous other comorbidities, contributing to the emergence of multimorbidity. The sustained rise in multimorbidity and AF prevalences exerts a significant strain on healthcare systems globally. The understanding of the relation between multimorbidity and AF is essential to determine effective healthcare strategies, improve patient outcomes to adequately address the burden of AF. It not only begins with the accurate identification of comorbidities in the setting of AF. There is also the need to understand the pathophysiology of the different comorbidities and their common interactions, and how multimorbidity influences AF perpetuation. To manage the challenges that rise from the increasing incidence and prevalence of both multimorbidity and AF, such as adverse events and hospitalisations, the treatment of comorbidities in AF has already gained importance and will need to be a primary focus in the forthcoming years. There are numerous challenges to overcome in the treatment of multimorbidity in AF, whereby the identification of comorbidities is essential. Integrated care strategies focused on a comprehensive multimorbidity management with an individual-centred approach need to be determined to improve healthcare strategies and reduce the AF-related risk of frailty, cardiovascular diseases and improve patient outcomes.

摘要

心房颤动(AF)的发病率和患病率呈上升趋势。AF 与许多其他合并症有关,导致多种合并症的出现。多种合并症和 AF 患病率的持续上升给全球的医疗保健系统带来了巨大压力。了解多种合并症与 AF 之间的关系对于确定有效的医疗保健策略、改善患者预后以充分应对 AF 负担至关重要。它不仅需要在 AF 背景下准确识别合并症。还需要了解不同合并症的病理生理学及其常见相互作用,以及多种合并症如何影响 AF 的持续存在。为了应对多种合并症和 AF 发病率和患病率上升带来的挑战,如不良事件和住院治疗,AF 中合并症的治疗已经变得重要,并且需要成为未来几年的主要关注点。在治疗 AF 中的多种合并症时存在许多挑战,其中识别合并症至关重要。需要确定以个体化为中心的综合多合并症管理为重点的综合护理策略,以改善医疗保健策略,降低 AF 相关的虚弱、心血管疾病风险,并改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/fb09dc7f9928/openhrt-2024-002641f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/18f6458a7a71/openhrt-2024-002641f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/d31cba103c33/openhrt-2024-002641f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/fb09dc7f9928/openhrt-2024-002641f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/18f6458a7a71/openhrt-2024-002641f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/d31cba103c33/openhrt-2024-002641f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8235/10952871/fb09dc7f9928/openhrt-2024-002641f03.jpg

相似文献

1
Multimorbidity in patients with atrial fibrillation.心房颤动患者的多种合并症。
Open Heart. 2024 Mar 19;11(1):e002641. doi: 10.1136/openhrt-2024-002641.
2
Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study.基层医疗中房颤、抗凝治疗、脑血管事件风险与多种疾病并存之间的关联:一项基于注册登记的研究
BMC Cardiovasc Disord. 2016 Mar 28;16:61. doi: 10.1186/s12872-016-0235-1.
3
Multimorbidity in atrial fibrillation for clinical implications using the Charlson Comorbidity Index.使用 Charlson 合并症指数评估心房颤动的多种合并症及其对临床的影响。
Int J Cardiol. 2024 Mar 1;398:131605. doi: 10.1016/j.ijcard.2023.131605. Epub 2023 Nov 22.
4
The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.移动医疗技术支持路径对合并多种疾病患者心房颤动相关不良事件的影响:mAFA-II 随机临床试验。
JAMA Netw Open. 2021 Dec 1;4(12):e2140071. doi: 10.1001/jamanetworkopen.2021.40071.
5
Cardiovascular and renal multimorbidity increase risk of atrial fibrillation in the PREVEND cohort.心血管和肾脏多重合并症增加 PREVEND 队列中房颤的风险。
Open Heart. 2023 Jul;10(2). doi: 10.1136/openhrt-2023-002315.
6
Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.优化房颤易感性和负荷指标,以评估房颤严重程度、风险和结局。
Cardiovasc Res. 2021 Jun 16;117(7):1-21. doi: 10.1093/cvr/cvab147.
7
Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation.老年心房颤动患者的多种合并症、身体虚弱和自我评估健康状况。
BMC Geriatr. 2020 Sep 11;20(1):343. doi: 10.1186/s12877-020-01755-w.
8
Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation.基于发病率负担的老年心房颤动患者管理:来自 Get With The Guidelines-Atrial Fibrillation 的见解。
J Am Heart Assoc. 2020 Dec;9(23):e017024. doi: 10.1161/JAHA.120.017024. Epub 2020 Nov 26.
9
Impact of Adverse Health Conditions on Clinical Outcomes of Older People with Atrial Fibrillation: Insights from a Prospective Cohort Study.不良健康状况对老年心房颤动患者临床结局的影响:一项前瞻性队列研究的启示。
Clin Interv Aging. 2024 Sep 6;19:1519-1528. doi: 10.2147/CIA.S464044. eCollection 2024.
10
Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.解决房颤患者的共病和多重用药问题。
Curr Cardiol Rep. 2018 Mar 24;20(5):32. doi: 10.1007/s11886-018-0975-x.

引用本文的文献

1
Radiomic features of peri-left atrial epicardial adipose tissue and atrial fibrillation recurrence after ablation.左心房周围心外膜脂肪组织的放射组学特征与消融术后房颤复发
Open Heart. 2025 Jul 8;12(2):e003364. doi: 10.1136/openhrt-2025-003364.
2
The burden of atrial fibrillation/atrial flutter in Europe from 1990 to 2021, with a forecast of incidence through 2044.1990年至2021年欧洲心房颤动/心房扑动的负担,并预测至2044年的发病率。
Front Cardiovasc Med. 2025 Jun 18;12:1606024. doi: 10.3389/fcvm.2025.1606024. eCollection 2025.
3
Patients' experiences of atrial fibrillation and comorbidity management in clinical practice: a pan-European qualitative descriptive interview study.

本文引用的文献

1
Lifestyle factors as mediators of area-level socioeconomic differentials in mental health and cognitive function: the Tromsø Study.生活方式因素作为地区层面社会经济差异在心理健康和认知功能方面的中介因素:特罗姆瑟研究
J Epidemiol Community Health. 2023 Nov 22;78(2):88-97. doi: 10.1136/jech-2023-220928.
2
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
3
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
患者在临床实践中对心房颤动及合并症管理的体验:一项泛欧洲定性描述性访谈研究
BMJ Open. 2025 Jun 16;15(6):e094839. doi: 10.1136/bmjopen-2024-094839.
4
Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation.心房颤动患者中与多种疾病、虚弱和营养不良相关的不良临床结局。
J Nutr Health Aging. 2025 Jan;29(1):100430. doi: 10.1016/j.jnha.2024.100430. Epub 2024 Nov 29.
frail 老年房颤患者由维生素 K 拮抗剂转换为非维生素 K 拮抗剂口服抗凝剂的安全性:FRAIL-AF 随机对照试验结果。
Circulation. 2024 Jan 23;149(4):279-289. doi: 10.1161/CIRCULATIONAHA.123.066485. Epub 2023 Aug 27.
4
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.司美格鲁肽治疗射血分数保留的心力衰竭合并肥胖患者的疗效。
N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
5
Cardiovascular and renal multimorbidity increase risk of atrial fibrillation in the PREVEND cohort.心血管和肾脏多重合并症增加 PREVEND 队列中房颤的风险。
Open Heart. 2023 Jul;10(2). doi: 10.1136/openhrt-2023-002315.
6
EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).EHRA 专家共识文件:衰弱综合征相关心律失常管理,由心律学会(HRS)、亚太心律学会(APHRS)、拉丁美洲心律学会(LAHRS)和南非心脏节律学会(CASSA)共同认可。
Europace. 2023 Apr 15;25(4):1249-1276. doi: 10.1093/europace/euac123.
7
Measuring multimorbidity in research: Delphi consensus study.研究中多重疾病的测量:德尔菲共识研究。
BMJ Med. 2022 Jul 27;1(1):e000247. doi: 10.1136/bmjmed-2022-000247. eCollection 2022.
8
Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis.社区环境中成年人群体多重疾病的全球和区域患病率:一项系统评价和荟萃分析。
EClinicalMedicine. 2023 Feb 16;57:101860. doi: 10.1016/j.eclinm.2023.101860. eCollection 2023 Mar.
9
Epidemiology and modifiable risk factors for atrial fibrillation.房颤的流行病学和可改变的危险因素。
Nat Rev Cardiol. 2023 Jun;20(6):404-417. doi: 10.1038/s41569-022-00820-8. Epub 2023 Jan 4.
10
Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives.连接心外膜脂肪组织与射血分数保留心力衰竭:机制、处理和现代观点。
Eur J Heart Fail. 2022 Dec;24(12):2238-2250. doi: 10.1002/ejhf.2741. Epub 2022 Nov 29.